Emir Derviş

Dr. Emir Derviş

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
AHAykun Hakgor
Aykun Hakgor
FOFatih Erkam Olgun
Fatih Erkam Olgun
ADAtakan Dursun
Atakan Dursun
BKBasak Catalbas Kahraman
Basak Catalbas Kahraman
AAAysel Akhundova
Aysel Akhundova
FKFethi Kilicaslan
Fethi Kilicaslan
Although sodium–glucose cotransporter 2 inhibitors (SGLT2i) are known to reduce the incidence of atrial fibrillation (AF) and AF-related adverse events, evidence on their prognostic effect in patients undergoing catheter ablation (CA) for AF is limited. In a single center, 614 patients (mean age 58.1 ± 9.9 years, 42.2% female) who underwent CA for AF were retrospectively divided into 2 groups according to SGLT2i treatment after the index procedure and followed up for 24 months. The primary outcome of the study was AF recurrence after the first 90-day blanking period after CA. Two separate Cox regression models were constructed to determine the predictors of AF recurrence. Rates of the primary outcome were 19.4% and 35.7% in the SGLT2i and non-SGLT2i groups, respectively. According to the multivariable model 1, which was established among the clinically relevant variables that were found to be statistically significant in univariable analysis, left atrial diameter (adjusted HR: 1.087, 95% CI, 1.054–1.122, P < 0.001), SGLT2i therapy (adjusted HR: 0.436, 95% CI, 0.286–0.665, P < 0.001), and nonparoxysmal AF (adjusted HR: 1.549, 95% CI, 1.039–2.309, P = 0.032) were independent predictors of recurrence after ablation. In model 2, SGLT2i treatment remained an independent predictor of AF recurrence along with significant variables such as age, heart failure with reduced ejection fraction, and previous stroke (adjusted HR: 0.315, 95% CI, 0.214–0.461, P < 0.001). The favorable efficacy of SGLT2i on the primary outcome was maintained in subgroup analyses. SGLT2i treatment is associated with lower recurrence after CA for AF in subgroups with and without diabetes or heart failure with reduced ejection fraction and in the overall patient population, independent of AF phenotype.


Verified
Journal Article
Open access
PDF file
HKHasan Can Konte
Hasan Can Konte
EDEmir Derviş
Emir Derviş
IYIdris Yakut
Idris Yakut
DADursun Aras
Dursun Aras
Background: Atrial fibrillation (AF) recurrence following catheter ablation remains a significant clinical challenge despite technological advancements, with recurrence rates in the range of 20–40%. While left atrial parameters have been extensively studied as predictors of recurrence, the contribution of right atrial mechanical function has received limited attention. The hypothesis that the combined assessment of right and left atrial strain parameters may provide superior predictive value represents an important clinical question with potential implications for post-ablation risk stratification and follow-up strategies. Methods: This single-center, retrospective cohort study included 100 consecutive adult patients who underwent AF ablation between May 2022 and June 2024 with at least one-year follow-up. Patients were divided into two groups: those with recurrence (n = 13) and those without recurrence (n = 87). A comprehensive echocardiographic assessment, including the speckle-tracking strain analysis of both atria, was performed. Results: The median follow-up was 365 days [range: 150–912 days] in patients with recurrence. In the multivariable analysis, right ventricular diameter (OR: 0.74; 95% CI: 0.61–0.90; p = 0.001), left ventricular end-diastolic volume (OR: 1.04; 95% CI: 1.00–1.08; p = 0.022), and left ventricular global longitudinal strain rate (OR: 1.22; 95% CI: 1.05–1.40; p = 0.007) emerged as independent predictors of recurrence. Conclusions: The significant association of right atrial longitudinal reservoir strain with recurrence in univariable analysis, although not retained as an independent predictor in the multivariable model, suggests the importance of comprehensive cardiac assessment including right heart parameters in predicting AF recurrence.

25 June 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
EDEmir Derviş
Emir Derviş
IYIdris Yakut
Idris Yakut
DIDuygu Inan
Duygu Inan
Objective: We aimed to investigate the association between the pan-immune-inflammation value (PIV) and mortality in patients with heart failure with a reduced ejection fraction (HFrEF), along with clinical and biochemical parameters. Methods: In this retrospective cohort study, 419 patients diagnosed with HFrEF between January 2014 and December 2023 were analyzed. Data on demographic features, comorbidities, cardiac parameters [New York Heart Association (NYHA) classification, left ventricular ejection fraction (LVEF), ventricular dimensions], medication use, and laboratory findings (PIV, N-terminal pro-B-type natriuretic peptide [NT-proBNP], electrolytes, and complete blood count) were collected from institutional and national records. Results: Mortality occurred in 22.91% of patients. PIV > 696 was significantly associated with mortality (sensitivity: 37.5%, specificity: 78.64%, p = 0.006), but it was not an independent predictor in multivariate analysis. Instead, low body mass index (BMI), increased end-systolic diameter, reduced LVEF, advanced NYHA class (III/IV), elevated NT-proBNP, hyponatremia, and lymphopenia were identified as independent predictors (all p < 0.001). Conclusions: Although PIV was associated with mortality in patients with HFrEF, it did not independently predict outcomes beyond established risk factors. These results suggest that while inflammation may contribute to HFrEF pathophysiology, traditional clinical and biochemical markers remain more reliable for prognostication.

25 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HKHasan Can Konte
Hasan Can Konte
EDEmir Derviş
Emir Derviş
MÇMehmet Serkan Çetin
Mehmet Serkan Çetin
OAOmer Alyan
Omer Alyan
DADursun Aras
Dursun Aras
Objectives: This study aimed to evaluate the predictive value of the neutrophil percentage-to-albumin ratio (NPAR) and other inflammatory indices for contrast-induced acute kidney injury (CI-AKI) in patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Methods: This retrospective cohort study included 317 ACS patients (aged ≥18 years) undergoing PCI between May 2022 and July 2024 at a single center in Turkey. Patients were divided into two groups based on CI-AKI development: those who developed CI-AKI (n = 35, 11.1%) and those who did not (n = 282, 88.9%). Data on demographics, clinical variables, and laboratory parameters (complete blood count, biochemistry) were collected from medical records. Inflammatory indices (neutrophil percentage-to-albumin ratio [NPAR], neutrophil-to-lymphocyte ratio [NLR], systemic immune–inflammation index [SII], pan-immune–inflammation value [PIV], systemic inflammation response index [SIRI]) were calculated. CI-AKI was defined as a ≥0.5 mg/dL absolute or ≥25% relative increase in serum creatinine within 48–72 h after contrast exposure. Results: The CI-AKI group demonstrated significantly higher neutrophil counts (p < 0.001) and neutrophil percentages (p < 0.001) and lower lymphocyte counts (p = 0.024) compared to the non-CI-AKI group. Baseline creatinine was lower in CI-AKI patients (p = 0.001) but showed significantly greater post-procedural increases (p = 0.008). All inflammatory indices predicted CI-AKI development, with NPAR showing superior performance: NPAR (AUC = 0.896, sensitivity 82.9%, specificity 84.0%), NLR (AUC = 0.732), SII (AUC = 0.694), PIV (AUC = 0.674), and SIRI (AUC = 0.709) (all p < 0.001). Independent predictors of CI-AKI included NPAR >18.44 (OR = 8.511, 95% CI: 2.763–26.212, p < 0.001), SIRI > 2.4 × 103 (OR = 2.991, p = 0.036), neutrophil count (OR = 1.707, p = 0.008), beta-blocker use (OR = 13.037, p = 0.016), and atrial fibrillation (OR = 8.042, p = 0.044). Conclusions: NPAR emerges as an accessible biomarker for predicting CI-AKI in ACS-PCI patients, which is also superior to other inflammation indices. We believe it is necessary to recommend its integration into risk stratification to improve outcomes among PCI recipients.

23 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EDEmir Derviş
Emir Derviş
EOEyup Ozkan
Eyup Ozkan
IYIdris Yakut
Idris Yakut
HKHasan Can Konte
Hasan Can Konte
AHAykun Hakgor
Aykun Hakgor
DADursun Aras
Dursun Aras
Background: We aimed to assess the uric acid-to-high-density lipoprotein cholesterol (HDL-C) ratio (UHR) and several other parameters with respect to their performance in detecting recurrence among patients with atrial fibrillation (AF) who underwent ablation. Methods: This retrospective cohort study analyzed data from patients who underwent radiofrequency or cryoablation for paroxysmal, persistent, or long persistent AF between September 2021 and September 2023. After ablation, patients were monitored for 24 h, with an ECG Holter used for symptomatic cases. Follow-up visits occurred at 1, 3, and 12 months. Collected data included demographics, comorbidities, echocardiographic measurements, clinical data, ablation type, medication use, and a comprehensive set of laboratory findings. Results: The study included 163 patients, with AF recurrence in 39 (23.93%) patients. Mean age was 57.49 ± 11.22 years, and 59.51% of participants were male. There was no significant difference between recurrent and non-recurrent groups in terms of age or sex distribution. Univariate analysis showed that recurrent patients had significantly larger left atrium diameter, higher percentages of persistent/long AF, and elevated levels of CRP, uric acid, UHR, and uric acid-to-creatinine ratio (UCR). Logistic regression analysis revealed that high left atrium diameter, long persistent AF presence, high CRP and uric acid levels, and high UCR and UHR values greater than 15.1 were independent predictors of AF recurrence. A UHR value of >15.1 was found to predict recurrence with 61.54% sensitivity and 70.97% specificity. Conclusions: Despite low sensitivity, UHR appears to be an independent biomarker that can predict AF recurrence. Including UHR in future risk assessment tools may be beneficial to enhance their accuracy.